Shares of Adaptimmune Therapeutics skyrocketed after the company announced an agreement to develop and commercialize allogeneic cell therapies for cancer with Genentech.
Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies.
Theravance announced that the diversified biopharmaceutical company’s oral drug candidate for the possible treatment of ulcerative colitis failed to meet the primary endpoint of a Phase IIb study.
International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.
Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.
California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.
Pfizer announced a second collaboration agreement with Arvinas to develop and commercialize the Connecticut-based company’s PROTAC estrogen receptor protein degrader.
Thermo Fisher Scientific launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as the company engages in more large-scale cohort studies and clinical research.
Global pharmaceutical operations and technology company Biogen partnered with Chinese commercial-stage biopharmaceutical firm InnoCare Pharma to develop a treatment for multiple sclerosis.
ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK, July 1, 2021 /PRNewswire/ — ObvioHealth, a global Virtual Research Organization (VRO), announces it […]